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Genetic variations in the vacuolar protein sorting 10 protein (Vps10p) family have been
linked to Alzheimer’s disease (AD). Here we demonstrate deposition of fragments from
the Vps10p member sortilin at senile plaques (SPs) in aged and AD human cerebrum.
Sortilin changes were characterized in postmortem brains with antibodies against the
extracellular and intracellular C-terminal domains. The two antibodies exhibited identical
labeling in normal human cerebrum, occurring in the somata and dendrites of cortical
and hippocampal neurons. The C-terminal antibody also marked extracellular lesions
in some aged and all AD cases, appearing as isolated fibrils, mini-plaques, dense-
packing or circular mature-looking plaques. Sortilin and β-amyloid (Aβ) deposition were
correlated overtly in a region/lamina- and case-dependent manner as analyzed in the
temporal lobe structures, with co-localized immunofluorescence seen at individual SPs.
However, sortilin deposition rarely occurred around the pia, at vascular wall or in areas
with typical diffuse Aβ deposition, with the labeling not enhanced by section pretreatment
with heating or formic acid. Levels of a major sortilin fragment ∼15 kDa, predicted to
derive from the C-terminal region, were dramatically elevated in AD relative to control
cortical lysates. Thus, sortilin fragments are a prominent constituent of the extracellularly
deposited protein products at SPs in human cerebrum.
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INTRODUCTION
Senile plaques (SPs) were first described by Blocq and Marinesco in examination of silver
stained brain samples from elderly epileptic patients (Critchley, 1929). The lesion was observed
subsequently in the brains of elderly with and without dementia by other pioneer neuroscientists
(e.g., Redlich, Alzheimer, Persini, Oppenheim, Fisher, Cajal), and it was Simvhowisz who named
the pathology as ‘‘senile plaques’’ (Critchley, 1929; García-Marín et al., 2007; Ohry and Buda, 2015).
Based on the silver preparation, it was also known by that time that SPs contained swollen neurites
and some amorphous material—the former was named as dystrophic neurites (DNs) while the
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entire lesion as neuritic plaques. The term ‘‘amyloid plaques’’
was coined later by Divry who found Congo red stain of
the amorphous material (Oı̆fa, 1973). Electron microscopic
studies and evidence from immunolabeling of presynaptic and
neurotransmitter markers (e.g., synaptophysin (SYN), choline
acetyltransferase, tyrosine hydroxylase, glutamate decarboxylase
and vesicular glutamate transporters) in plaque-associated DNs
suggest that they appear to be largely abnormal axons including
presynaptic terminals (Luse and Smith, 1964; Gonatas et al., 1967;
Struble et al., 1982, 1987; Walker et al., 1985; Masliah et al., 1991;
Ferrer et al., 1998; Cai et al., 2010; Yan et al., 2014; Sadleir et al.,
2016).
By the mid-1980s, β-amyloid peptides (Aβ) were identified
from amyloid vasculature and parenchymal plaques in the
human brain, marking a milestone in the history of research
on cerebral β-amyloidosis relative to Alzheimer’s disease (AD;
Glenner and Wong, 1984; Masters et al., 1985). Within a few
years antibodies to Aβ became routine tools to stain SPs for
definitive diagnosis of AD. Site-specific deposition of Aβ at
cerebral vasculature, meninge and diffuse plaques in the gray
and white matter (WM) was also confirmed (Allsop et al., 1986;
Jellinger and Bancher, 1988; Yamaguchi et al., 1988; Braak and
Braak, 1991; Braak et al., 2006). The discovery of Aβ as the key
components of cerebral β-amyloidosis has since led to many
other breakthroughs in the AD research field and beyond,
as partially listed: (1) characterization of the amyloidogenic
proteins, i.e., β-amyloid precursor protein (APP), β-secretase-1
(BACE1) and γ-secretase complex (Robakis et al., 1987; Wolfe
and Haass, 2001; Vassar et al., 2009); (2) establishment of the
genetic link of APP and presenilin mutations to familial AD
(Shea et al., 2016); (3) engineering of transgenic animal models
of AD (Hsiao et al., 1996; Borchelt et al., 1997; Oddo et al., 2003;
Oakley et al., 2006); (4) development of cerebrospinal fluid
(CSF) biomarkers and Aβ imaging techniques for antemortem
diagnosis of AD (Andreasen et al., 2001; Mathis et al., 2002;
Herholz and Ebmeier, 2011); and (5) conceptualization of the
anti-Aβ therapy that has advanced from bench to bedside testing
(Aisen, 2005; Yan et al., 2014; Karran and De Strooper, 2016).
Notably, some blood proteins, heavy metals and lipoproteins
accumulate around amyloid plaques (Coria et al., 1988; Rogers
et al., 1992; Schwarzman et al., 1994; Eriksson et al., 1995;
Kida et al., 1995; Watson et al., 1997; Burns et al., 2003; Wu
et al., 2004; Garai et al., 2014; Cristóvão et al., 2016). Exploring
additional plaque constituents, if any, may also help advance
the understanding of plaque pathogenesis in the brain.
Variations in the vacuolar protein sorting 10 protein (Vps10p)
family genes are recently shown to affect the risk of developing
AD (Westergaard et al., 2004; Hermey, 2009). Variants in several
loci of the sortilin-related receptor L1 gene (SORL1, also known
as SORLA, SORLA1 or LR11) can increase the risk of AD
(Rogaeva et al., 2007; Pottier et al., 2012; Wen et al., 2013; Felsky
et al., 2014; Louwersheimer et al., 2015; Verheijen et al., 2016).
Variants of single nucleotide polymorphisms (SNPs) of the
sortilin related Vps10p domain containing receptor 1 (SORCS1)
may also relate to AD (Reitz et al., 2011). The SNP rs17646665 of
the sortilin gene (SORT1) is linked to a reduced risk of AD
(Andersson et al., 2016). The Vps10p proteins belong to type
I transmembrane proteins, which might subject to proteolytic
processing (Avci and Lemberg, 2015). The gene-association data
obtained from human populations raise an intriguing issue as
to whether the expression of some proteins from this family,
including their potential fragment products, might be altered
relative to AD-type neuropathology.
With the setup of human brain banks, a preliminary batch
of postmortem brains from Chinese donors became available
for aging and AD-related studies (Zhu et al., 2015; Griffith
et al., 2016). Using this resource, we conducted a pilot survey
on the expression of the Vps10p members in the brain with
commercial antibodies, and noticed that a sortilin C-terminal
antibody visualized extracellular lesions appearing as amyloid
plaques. Experiments were then carried out to verify this sortilin
pathology, to profile its relationship with Aβ deposition and to
identify the candidate peptide component seen deposited in the
plaques.
MATERIALS AND METHODS
Human and Rodent Brain Samples
Postmortem human brains were banked through the willed body
donation programs, which existed with government (municipal
police department and office of the Red Cross Society of
China) and university approval to provide cadavers for teaching
anatomy to medical students. Efforts are being taken to develop
this platform for human brain banking as a part of the initiatives
supporting China Brain Project (Yan et al., 2015; Poo et al.,
2016). A subgroup of the elderly cases was recorded being
dementia at the time of hospitalization for the care of terminal
illnesses (Supplementary Table S1). Brain samples were assessed
for AD type-neuropathology using sections from temporal,
parietal, frontal and occipital lobes, with the extent of pathology
(if present) scored according to Braak’s staging and the NIH
guideline (Jellinger and Bancher, 1988; Braak et al., 2006;
Montine et al., 2012). Correlated anatomical and biochemical
studies were carried out using samples from three groups
designated according to age and AD-type neuropathology:
(1) Mid-age cases (n = 9) died of non-neurological diseases and
free of Aβ/tau pathology in the cerebrum; (2) Aged cases (n = 9)
with a history of dementia but Braak’s score of neurofibrillary
tangle ≥ IV and the ABC amyloid score ≥ B, defined as AD
group, and (3) Aged control group (n = 9) with no Aβ/tau
pathology observed in the brain. It should be noted that, for
comparative pathological analyses, additional aged cases with
cerebral amyloidosis were included (Supplementary Table S1).
Through this latter approach, brain samples/cases exhibiting
a spectrum of AD-type neuropathology were used to allow a
correlated morphometric analysis on Aβ and sortilin pathologies.
Brains from sortilin knockout (−/−, n = 4), wildtype (+/+,
n = 4) and C57BL/6 mice were used for the purpose of
antibody validation (Ruan et al., 2016), with hemi-brains
obtained after vascular rinse with cold saline then prepared
for immunohistochemistry and immunoblot, respectively. The
use of postmodern human brains and laboratory animals was
approved by the Ethics Committees of Central South University
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Xiangya School of Medicine and Chinese Academy of Medical
Sciences, Institute of Basic Medical Sciences (human brain
study), and the Animal Ethic Committee of SA Pathology at
Adelaide, Australia (mouse brain study), in compliance with the
Code of Ethics of the World Medical Association (Declaration
of Helsinki) and the National Institutes of Health Guide for the
Care and Use of Laboratory Animals.
Tissue Processing
Postmortem human brains were bisected and cut into
∼2 cm-thick frontal slices. Slices from one hemisphere (opposite
to handedness) were fixed in formalin for at least 1 week, with
the slices from the other hemi-brain stored at−70◦C. Temporal,
frontal, parietal and occipital lobe blocks were then sampled from
the fixed hemisphere, and either embedded with wax or placed
in 30% sucrose in 0.01 M phosphate buffer, which were further
prepared into paraffin (5 µm thick) or cryostat (40 µm thick)
sections. The cryostat sections were collected in phosphate-
buffered saline (PBS, 0.01 M, pH 7.2), with consecutive sections
placed orderly into 24 wells each containing 4–6 sections/block
with equal distance (24 × 40 ≈ 1000 µm). The sections were
rinsed with PBS twice to remove the embedding medium, and
stored in a cryoprotectant at −20◦C before use. Mouse brains
were dissected out after vascular perfusion with cold saline, with
hemi-brains either snap-frozen for biochemical study or fixed by
immersion in 4% paraformaldehyde for anatomical study.
Immunohistochemistry and
Immunofluorescence
Four sets of consecutive mid-hippocampal temporal lobe
sections from each brain, 4–6 cases together in each experiment,
were stained immunohistochemically with four antibodies:
goat anti-sortilin extracellular domain (diluted at 1:2000,
AF3154, immunogenic peptide corresponding to amino
acid (a.a.) 76–753 of human sortilin, AF3154-SP, R&D
Systems China Co. Ltd., Shanghai, China), rabbit anti-sortilin
intracellular C-terminal domain (1:2000, ab16640, immunogenic
peptide corresponding to a.a. 800–831 of human sortilin,
ab16686, Abcam Trading Shanghai Company Ltd., Shanghai,
China), monoclonal mouse anti-Aβ 6E10 (1:5000, #39320,
Signet Laboratories Inc., Dedham, MA, USA) and rabbit
anti-phosphorylated tau (1:5000, T6819, Sigma-Aldrich, St.
Louis, MO, USA). In this set of experiments, the sections
subjected to 6E10 labeling were invariably pretreated with
formic acid for 1 h at room temperature. To determine the
effect of several section pretreatments, including sortilin
immunogenic peptide blocking (at 5 and 10 times of primary
antibody concentration), heating (65◦C), formic acid (100%)
and guanidine hydrochloride (HCl; 5 M) treatments, consecutive
sections from four brains with extensive amyloid pathology were
selected for each treatment paradigm. Also, in each experiment,
several adjacent sections were processed together with other
sections, excluding the primary antibody in the incubation
buffer, which were used to obtain the cutoff level of nonspecific
labeling in densitometry.
Other than the above specifications, all sections were treated
free-floating first with 5% H2O2 in PBS for 30 min and 5%
normal horse serum in PBS with 0.3% Triton X-100 for 1 h,
followed by incubation with the primary antibodies at 4◦C
overnight. The sections were then reacted with biotinylated
horse anti-mouse, rabbit and goat IgGs at 1:400 for 1 h and
ABC reagents (1:400; Vector Laboratories, Burlingame, CA,
USA) for 1 h, with the immunoreactivity visualized in 0.003%
H2O2 and 0.05% 3,3′-diaminobenzidine. Immunolabeling on
paraffin sections was processed on-slide following dewaxing,
rehydration and the antibody incubation steps described above,
which involved Aβ, p-Tau, and sortilin immunolabeling with the
rabbit antibody. The immunolabeled sections were used for the
scoring of the AD type-pathology (i.e., ABC staging for amyloid
pathology and Braak’s I–VI staging for tau pathology (Braak
et al., 2006; Montine et al., 2012), and for an overall assessment
for the presence of extracellular sortilin labeling relative to the
occurrence of Aβ deposition.
Double immunofluorescence was initiated with section
pretreatment in PBS containing 5% donkey serum for 30 min.
The sections were then incubated overnight at 4◦C with the
rabbit sortilin antibody (ab16640, 1:1000), together with one of
the following: (1) goat anti-sortilin (AF3154, 1:1000); (2) 6E10
(1:4000); (3) mouse anti-SYN (1:1000; MAB329, Millipore,
MA, USA); (4) mouse anti-phosphorylated tau (PHF1, courtesy
of Dr. P Davis, 1:4000); (5) mouse anti-glial fibrillary acidic
protein (GFAP, 1:2000; MAB360, Millipore); and (6) mouse
anti-ApoE (1:1000, NE1004, Millipore). Immunofluorescence
was visualized with Alexa Fluorr 488 and Alexa Fluorr
594 conjugated donkey anti-mouse, anti-rabbit or anti-goat
IgGs (1:200, Invitrogen, Carlsbad, CA, USA). The sections were
treated with 0.1% Sudan black to block autofluorescence before
microscopic examination.
Western Blot
Preparation of tissue lysates and electrophoresis were carried
out with caution to minimize the effect of temperature on
protein degradation. Neocortex from the middle temporal
gyrus of the frozen human cerebral hemispheres and frontal
cortex from frozen mouse brains were sampled in the chamber
of cryostat, then homogenized on ice by sonication in T-PER
extraction buffer (Pierce, Rockford, IL, USA) containing protease
inhibitors (Roche, Indianapolis, IN, USA). Resulting lysates were
centrifuged at 15,000 g at 4◦C, with supernatants collected
and protein concentrations measured by DC protein assay
(Bio-Rad Laboratories, Hercules, CA, USA). Extracts containing
equal amount of total protein were run in SDS-polyacrylamide
gel electrophoresis (PAGE) gels (protein loading and SDS
concentration to be detailed along with result description).
Separated protein products were electrotransferred to Trans-Blot
pure nitrocellulose membranes, which were immunoblotted
with the aforementioned antibodies (rabbit and goat anti-sortilin
diluted at 1:2000, 6E10 at 1:4000, BACE1 at 1:2000 and
phosphorylated tau at 1:2000; Cai et al., 2010), and that for
loading controls including β-tubulin-III (1:5000, Millipore),
β-actin (1:5000, Millipore) or glyceraldehyde-3-phosphate
dehydrogenase (GAPDH; 1:5000, Millipore). The membranes
were further reacted with HRP-conjugated secondary antibodies
(1:20,000; Bio-Rad Laboratories). Immunoblotting signal was
Frontiers in Neuroanatomy | www.frontiersin.org 3 June 2017 | Volume 11 | Article 45
Hu et al. Sortilin Deposition at Plaques
visualized with the ECL-Plus detection kit, followed by X-ray
film exposure and image capture in a laser scanner.
Imaging, Data Analysis and Figure
Preparation
Immunolabeled sections were examined on an Olympus
BX51 microscope and a Nikon confocal microscope equipped
with digital imaging systems (CellSens Standard and Nikon-EZ-
C1, respectively). Light microscopic images were taken using
2× to 40× objectives, with low magnification images montaged
to re-construct the labeling over the temporal lobe regions.
Confocal images were taken at 20× and 40× through three scans
covering∼6 µm tissue depth. Images prepared for densitometry
were obtained from comparable locations in adjacent sections
using the same light intensity and digital exposure pre-settings,
for all cases and all types of immunolabeling. Quantification of
immunolabeled profiles was carried out following incorporation
of region-matched images into a single file, which was converted
into gray-scale TIFF format. Subsequently, either the areas or
optic densities of the profiles/anatomic regions of interest were
measured with the OptiQuant software (Packard Instruments,
Meriden, CT, USA). Optic densities over immunoblotted protein
bands were obtained with the same software.
All image data were exported into Excel spreadsheets
and re-arranged according to groups, with specific densities
calculated by background subtraction, and areal fractions or
relative density levels calculated against internal references,
whenever applicable. Finally, all data were entered into Prism
spreadsheets, analyzed statistically, and graphed if applicable
(GraphPad Prism 4.1, San Diego, CA, USA). Statistical analyses
were conducted using either paired two-tailed t-test or a
nonparametric test (Kruskal–Wallis with Dunn’s multiple
comparison) with the GraphPad Prism software. Details
regarding group pairing, sample size and statistics for individual
tests will be incorporated in the following sections along with
result description as well as in figure legend. The minimal
significant level of difference was set at p < 0.05. Figures were
assembled with Photoshop 7.1.
RESULTS
Antibodies Against Sortilin Extracellular
and Intracellular Domains Displayed
Identical Neuronal Labeling in Adult
Rodent and Human Cerebrum
We validated the specificity of the sortilin antibodies to the
extracellular (goat) and intracellular C-terminal (rabbit) parts
using sortilin knockout (−/−) and wildtype (+/+) mouse brains
(Figures 1A–E; Ruan et al., 2016). Both antibodies marked a
∼100 kDa band in immunoblot of sortilin+/+, but not −/−,
lysates, representing a presence of the full-length protein in the
wild-type but not knockout mouse tissues (Figures 1B,D). By
extending the film exposure time, two bands at ∼15 kDa and
∼40 kDa became visible in the immunoblot with the C-terminal
antibody of the sortilin+/+, but not sortilin−/−, lysates
(Figure 1D), indicating the existence of specific sortilin-derived
peptides in the former preparation at very low concentration. In
immunohistochemistry, the two antibodies exhibited identical,
essentially neuronal, labeling in the sortilin+/+ mouse forebrain
(Figures 1C,E), whereas the labeling appeared background like
in sortilin−/− counterpart (Figures 1B,D). We also confirmed
a fully co-localized immunofluorescent labeling by the two
antibodies, occurring primarily in the somata and dendrites
of cortical and hippocampal pyramidal neurons as well as
the granule cells of dentate gyrus (DG) in wild-type rodents,
including at granular profiles inside the somata and large
dendrites (Figures 1F–M).
The two sortilin antibodies also exhibited identical labeling
pattern in mid-age human cerebrum (Figure 2). Thus,
immunolabeling in the neocortex occurred in the gray matter,
mainly over layers II–VI and heaviest in layers VI, with little
reactivity in the WM (Figures 2A,H). At higher magnifications,
pyramidal and polymorphic neurons in layers V/VI and II/III
were among the most distinctly labeled (Figures 2A,B,D). The
somata and apical dendrites of the subicular and hippocampal
pyramidal neurons were clearly visualized, with granular
elements visible in the cytoplasm (Figures 2C,E). In the
DG, both the granule cell layer (GCL) and molecular layer
(ML) showed heavy reactivity (Figures 2A,F). Hilar mossy
cells and CA3 pyramidal neurons, including their dendritic
trees, were well-labeled (Figures 2A,F,G,H,J), with the thorny
excrescences (TE) on the dendrites clearly identifiable at high
magnifications (Figures 2F,G,I,J). Overall, axonal profiles were
not identifiable around the somata of cortical and hippocampal
neurons (Figures 2D,E), nor in the cerebral WM (Figures 2A,H)
and in the mossy fiber terminal field (Figures 2A,F,H).
Sortilin C-Terminal Antibody Labeled
Plaque-Like Lesions in Aged and AD
Human Cerebrum
The sortilin antibodies against the extracellular and intracellular
domains exhibited sharply different labeling patterns in the
brains with AD-type pathology. Thus, the C-terminal antibody
visualized plaque-like lesions, whereas the extracellular domain
antibody did not (Figures 3A–H; Supplementary Figures S1, S2).
Notably, in the samples with extensive plaque lesions, the
neuronal labeling by the C-terminal antibody became less
impressive, compared to that by the extracellular domain
antibody (Figures 3A–D; Supplementary Figures S1, S2). This
phenomenon appeared to likely reflect a competitive situation
among the antigen epitopes in the section to bind the available
antibody, because we found that the neuronal labeling could be
enhanced by raising the concentration (from 1:2000 to 1:1000 or
1:500) of the rabbit antibody in the incubation buffer (data not
shown).
We carried out an overall assessment of the C-terminal
antibody labeling in sections from more than 70 brains with
and without amyloid and tau pathology (including 10 Caucasian
AD cases; Supplementary Table S1). Overall, the plaque-like
sortilin labeling was found consistently among the cases
that also had cerebral amyloid pathology. Thus, as assessed
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FIGURE 1 | Validation of sortilin antibodies using sortilin knockout (−/−) and wildtype (+/+) mouse brains, with a characterization of the normal expression pattern of
sortilin in rodent cerebrum. Panel (A) is a schematic drawing of the human sortilin protein, with the extracellular, transmembrane and intracellular domains of varying
lengths of amino acid (a.a.) residues as marked. The immunogenic synthetic peptide sequences for the extracellular and intracellular C-terminal domain antibodies
are also provided. Panels (B,C) show representative immunoblot and immunolabeling results obtained with the goat antibody (Gt Ab) against the extracellular domain
in sortilin +/+ and −/− brains. Panels (D,E) show the results obtained with the rabbit antibody (Rt Ab) against the intracellular C-terminal. Both antibodies label a
∼100 kDa band in sortilin +/+, but not in −/−, lysates (B,D). Several non-specific bands are visible in the immunoblot with the goat antibody, equally present in the
sortilin +/+ and −/− lysates, by extending the time of film exposure (B). With overexposure, two light bands at ∼40 and ∼15 kDa (pointed by arrow) are also
noticeable in the immunoblot of sortilin +/+ lysates with the rabbit antibody (D). Light microscopic images (C,E) show neuronal profiles in the subiculum (Sub) to
CA1 transitional region labeled by both antibodies in sortilin +/+, but not in −/−, brain sections. Confocal immunofluorescent images show completely colocalized
labeling by the two antibodies in cortical pyramidal-like neurons (F–I), CA3 pyramidal neurons and granule cells of the dentate gyrus (DG) (J–M) in C57BL mouse
brain, with granular elements seen intracellularly (I,M). Western blot applications: 12% SDS-PAGE gel and 13 µg equal amount protein loading. Additional
abbreviations: CC, corpus callosum; s.p., stratum pyramidale; GCL, granule cell layer; PC, Parietal cortex; I-III, cortical layers; GAPHD, glyceraldehyde-3-phosphate
dehydrogenase. Scale bar = 200 µm in (C) applying to (E); 100 µm in (F) applying to (G,H,J–L), equivalent to 25 µm for (I,M).
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FIGURE 2 | Characterization of the normal sortilin expression pattern in the human cerebral neocortex and hippocampal formation with tissue from a mid-age case.
Panel (A) is a montaged low magnification image illustrating the expression of sortilin labeled with the rabbit antibody across the superior, middle and inferior temporal
gyri (STG, MTG, ITG), subiculum (Sub), hippocampal Ammon’s horn (CA1–3) and DG. The labeling occurs in the gray matter but barely in the white matter (WM). The
molecular layer (ML) of the DG shows strong neuropil reactivity. Panels (B,D) show higher power views of the labeling in the neocortex, with large and middle-sized
pyramidal and polymorphic neurons exhibiting strong immunoreactivity. Panels (C,E) show heavy labeling in CA1 pyramidal neurons specifically in the somata and
dendrites, with the stratum radiatum (s.r.) also exhibiting strong reactivity in fine dendritic processes and neuropil. Panels (F,G) are higher magnification images of the
DG; the somata and proximal dendrites of the granule cells are intensively stained. The somata and dendrites of hilar mossy cells are distinctly labeled, with the thorny
excrescences (TE, arrows) well-displayed. Axons of the cortical and CA1 pyramidal neurons are not visible (D,E), with no labeling seen in the mossy fiber terminal
field (A,F). Panel (H) shows that the goat antibody exhibits essentially the same neuronal labeling pattern in the hippocampal formation and temporal neocortex as
with the rabbit antibody (A), with enlarged views specifically illustrating the visualization of the TE on the dendrites of the CA3 pyramidal neurons (I,J). Additional
abbreviations: IV-VI, cortical layers. Scale bar = 1 mm in (A), equivalent to 2 mm for (H), 200 µm for (B), 100 µm for (C,I), 50 µm for (D,F,J) and 25 µm for (E,G).
Frontiers in Neuroanatomy | www.frontiersin.org 6 June 2017 | Volume 11 | Article 45
Hu et al. Sortilin Deposition at Plaques
FIGURE 3 | Morphological characterization of sortilin labeled plaque lesions relative to amyloid and tau pathology using sections from cases with Alzheimer’s disease
(AD). Panels (A–G) show low and high power (framed areas) views over the hippocampal formation and part of temporal cortex (TC) from adjacent sections, with the
4 markers as indicated. The rabbit sortilin antibody labels plaque lesions that are regionally matched to that labeled by the 6E10 β-amyloid (Aβ) antibody (A,B,E,F).
Both the rabbit and goat sortilin antibodies label neuronal profiles seen clearly in the GCL at low magnification (a-d). Immunolabeling of phosphorylated Tau (p-Tau) is
seen in tangled neurons and neuritic plaques (G,H). Panels (I,J) are images taken from adjacent sections of the entorhinal cortex (Ent) from another AD case,
showing a lack of extracellular sortilin labeling at the layer II cell islands (pointed by arrowheads) that exhibited diffuse Aβ deposition. Panels (K,L) shows a lack of
sortilin deposition in association with cerebral amyloid angiopathy (CAA), also as assessed between consecutive sections. Asterisks denote the trajectory of a
longitudinally cut amyloid arteriole entering the cortex from pia surface, with the two arrowheads pointing to two cross-sectioned normal vessels, for additional spatial
reference. Panels (M–P) show high magnification views of extracellular sortilin deposits in sections counterstained with hematoxylin. Plaques occur in the ML of the
DG in a row (M), and in the cortex of the middle temporal gyrus (MTG) with different sizes and labeling intensity (N). Panel (O) shows the occurrence of small amount
of deposits (pointed by arrows) in the neuropil in areas about the sizes of the cell nuclei and neuronal somata, along with densely packed mature-looking plaques.
Panel (P) shows circular plaques with cell nuclei (arrows) in the center. Additional abbreviations: I-III, cortical layers; s.l.m., stratum lacunosum-moleculare; other
abbreviations are as defined in Figure 1. Scale bar = 1 mm in (A) applying to (C,E,G); equivalent to 200 µm for (B,D,F,I,J), 50 µm for (K–N) and 25 µm for (O,P).
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between consecutive temporal lobe sections, sortilin and Aβ
labeled plaques both occurred over the neocortex, subiculum
and hippocampal areas with their distributions matchable
in reference to given subregions and lamina, noticeable
at low magnification (Figures 3A,B,E,F; Supplementary
Figures S1, S2). As with Aβ plaques, sortilin plaques lacked
a spatial parallelism with tau pathology over the temporal
lobe regions (Figures 3A–H; Supplementary Figures S1, S2)
(therefore we did not quantitatively analyze sortilin relative to tau
pathology). While assessing the overall pattern of extracellular
sortilin/Aβ labeling, it should be notified that, along with the
compact-like lesions diffuse Aβ deposition was present in
local areas of the cortex, e.g., around layer I, the cell islands in
layer II of the entorhinal cortex and the WM. In comparison,
immunoreactivity of the C-terminal sortilin antibody in the
above anatomic locations appeared to be not changed (relative
to adjacent regions; Figures 3I,J; Supplementary Figures S2F,I).
Also as a general note, 6E10 was found to label β-amyloidosis
locally around the pia and blood vessels in the gray and WMs,
whereat no increased extracellular sortilin deposition was found
at these locations (Figures 3K,L).
At high magnifications more clearly in immunolabeled
sections with hematoxylin counterstain, the plaque-like lesions
detected with the sortilin C-terminal antibody consisted of
extracellularly deposited fibrillary products (Figures 3M–P).
The plaques were largely round, varying in size, often with
the fibrillary material densely packed across the entire plaque.
However, some plaques contained less densely stained fibrils
(Figure 3N). Coexisting with the above, labeled extracellular
fibrils were seen to deposit over small areas about the sizes of the
neuronal nuclei, or as mini-plaques of the sizes of the neuronal
perikarya (Figure 3O). Large sortilin plaque profiles could be
ring-like with the deposits packed on the periphery, leaving an
empty or pale center that sometimes occupied by cell nuclei
(Figure 3P).
We used immunogenic peptide absorption to verify the
specific labeling of the sortilin antibodies in the human
brain sections. The labeling of the rabbit antibody was
diminished to the background levels (defined using sections
processed in the absence of primary antibody), when the
immunohistochemistry was proceeded by co-incubation with the
C-terminal immunogenic peptide at either 5 (data not shown)
and 10 times of the concentration of the primary antibody
(Figures 4A,B,D,I). Such an effect did not occur by including
the extracellular domain peptide in the incubation buffer
(Figures 4A,C,I). Vice versa, the extracellular immunogenic
peptide could completely block the labeling of the goat antibody,
but did not affect the immunolabeling of the rabbit C-terminal
antibody (Figures 4E–H,J).
Sortilin and Aβ Deposition at Senile
Plaques were Anatomically Correlated in
Human Cerebrum
In a subset of the aged and AD cases we noticed sortilin/Aβ
plaques preferentially distributed along the ML of the DG, with
distinctly labeled plaques also present in the subiculum and
adjoining CA1 area (Figures 3K, 5). Therefore, we carried out
correlative areal ratio analyses of sortilin and Aβ plaques across
the ML and in a defined area of the CA1/subiculum region.
The fractional areas of the sortilin and Aβ plaques, expressed
as % area occupied, were plotted relative to individual cases
(Figures 5A,B,E). A strong positive correlation (P < 0.0001,
R2 = 0.932) between the fractional areas of sortilin and
Aβ plaques in the ML was found based on the analysis of
sections from 20 individuals (Figure 5F). In the CA1/subiculum
transitional region selected for quantification, the fractional
areas of sortilin and Aβ plaques were also positively correlated
(P < 0.0001, R2 = 0.983, n = 24) in a case-dependent
manner (Figures 5E,F). We further assessed if the overall
amounts of sortilin and Aβ deposition were correlated in the
neocortex, using a densitometric approach (Figure 5G). The
resulting densitometric data indicated a positive correlation
(P < 0.0001, R2 = 0.880, n = 15) between sortilin and
Aβ deposition in reference to individual brains (Figure 5H).
It should be noted that the total optic density measured
in a region reflected that contributed by labeled plaques as
well as neurons. In the case of Aβ immunolabeling, diffuse
plaques and vascular β-amyloidosis present in the measured
areas would also contribute to the yielded total optic density.
Nonetheless, the densitometric correlation reflected a trend
of overall parallelism between sortilin and Aβ extracellular
deposition in the neocortex.
In double immunofluorescence, only the rabbit antibody,
but not the goat antibody, labeled plaques, while there was
a colocalization of the labeling by the two antibodies in
neuronal somata (Figures 6A1–4). Colocalization of extracellular
sortilin and Aβ labeling at individual compact-like plaques
was clearly seen in the hippocampal and cortical regions,
shown for examples in the ML of the DG (Figures 6B1–4)
and the subiculum (Figures 6C1–4). Notably, while the
immunofluorescence appeared to be parallel in intensity
between the two markers across the entire area of a plaque
(Figures 6B1–4); it could be stronger for one marker than
the other over subareas of the same plaque (Figures 6C1–4).
Sortilin and SYN immunofluorescence co-existed at apparently
neuritic plaques, with SYN-labeled DNs surrounded by or
intermingled with extracellular sortilin labeling (Figures 6D1–4).
Extracellular sortilin labeling was also found to coexist with
neuritic elements with weak p-Tau immunofluorescence in
plaques (Figures 6E1–4). Hypertrophic astrocytes with bright
GFAP immunofluorescence were present in the vicinity of some
sortilin labeled plaques (Figures 6F1–4). Moreover, sortilin-
labeled plaques colocalized with extracellular ApoE labeling
(Figures 6G1–4).
Aβ-Enhancing Antigen Retrieval did not
Affect Extracellular Sortilin Labeling
Tissue processing and antigen retrieval, e.g., temperature,
formic acid and guanidine HCl, could affect Aβ aggregation
or Aβ immunodetection. We therefore explored if sortilin
labeling could be affected by some Aβ-enhancing antigen
retrieval methods. These experiments were carried out
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FIGURE 4 | Verification of the specific labeling of the two sortilin antibodies in neuronal and plaque profiles with immunogenic peptide absorption assay. Panels
(A–C) show representative images from sections processed with the rabbit antibody in the absence (A) and presence of the C-terminal (B) or the extracellular
domain (C) immunogenic peptide at 10 times of the concentration of the primary antibody. Panel (D) shows the background reactivity seen in the cortex from the
sections processed by excluding the primary antibody. Panels (E–H) show the labeling with the goat antibody arranged as indicated. Dot graphs (I,J) represent the
relative specific optic densities obtained from a set of precentral and a set of postcentral gyral sections, from each of four brains with stage C amyloid pathology. The
specific density is defined by subtracting the background from the total densities measured over layers I–VI of the same gyral region for each set of preparations, with
the background density obtained from the section processed by excluding the primary antibody (without hematoxylin counterstain). Data from individual sections
(i.e., totally eight sections) are normalized to the mean of the group with sections immunolabeled with the primary antibody only. To illuminate the cortical lamination,
the sections used to prepare the images shown in panels (B,D,G,H) have been lightly counterstained with hematoxylin. The C-terminal and extracellular domain
immunogenic peptides can selectively and completely block the immunolabeling of the corresponding sortilin antibodies (I,J). Results from statistical analysis
(Kruskal-Wallis analysis with post hoc test) between the indicated groups are as marked, with ∗noting P < 0.05 and NS noting not significant different (I,J). Scale
bar = 200 µm in (A) applying to other image panels.
by batch-processing consecutive frontal (blocked from the
precentral gyrus) and parietal (postcentral gyrus) neocortical
sections subjected to untreated and pretreated conditions. The
sections from four brains with stage C Aβ pathology were
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FIGURE 5 | Quantitative analysis of sortilin relative to β-amyloid deposition in hippocampal lamina and temporal neocortex. Panels (A,B) show labeling with the
rabbit sortilin antibody and 6E10 in consecutive temporal lobe sections used for quantification. The framed WM areas are enlarged to show diffuse Aβ labeling
(pointed by arrows, also in panel (A) along the pia) that is not associated with extracellular sortilin deposition (C,D). The pseudocolored screen print image (E)
illustrates the methodology to measure the fractional areas of sortilin and Aβ plaques manually over the ML and in the CA1/subiculum transitional region. The latter is
defined by two parallel lines passing the upper and lower edges of the GCL and between the hippocampal fissure and gray/WM border. Areas of individual plaques
are measured by tracing along their outer border using the irregular selecting line-drawing tool (OptiQuant software). The sum of plaque-occupied areas is divided by
the total area of the reference region, yielding the fractional areal value, expressed as % of area occupied, for each case. The fractional areal values for sortilin and Aβ
plaques are plotted against individual aged and AD cases, with sample size noted in the graphs. In both the ML and the CA1/subiculum transitional region, the
fractional areas of sortilin and Aβ plaques are positively correlated among the cases (F). Pseudocolored image (G) illustrates the methodology to obtain the total
densities of sortilin and 6E10 labeling over the same cortical area (layers I–VI) of the middle temporal gyrus (MTG) in consecutive sections, and to obtain the
background cutoff density from another adjacent section batch-processed excluding primary antibodies. Specific optic density is calculated by subtracting the
background from total densities. Panel (H) plots specific densities of sortilin and 6E10 immunolabeling relative to individual cases analyzed, showing a positive
correlation between the two measurements. Statistical results obtained via a nonparametric (Kruskal-Wallis) test are also marked in the graphs (F,H). Scale
bar = 1 mm in (A) applying to (B), equal to 250 µm for (C,D).
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FIGURE 6 | Double immunofluorescent characterization of sortilin labeling at neuritic plaques. Each set shows the immunolabeling with the rabbit sortilin antibody
relative to another marker, with bisbenzimide nuclear labeling included in the merged image. Imaged region and lamina are as indicated. Histograms illustrate the
relative intensity of the red and green fluorescence measured along the line marked in the fluorescent images, with arrows pointing to the locations of labeled cellular
or neuritic elements. Panels (A1–4) show a selective labeling by the rabbit sortilin antibody at plaques, while neuronal somata are labeled by both sortilin antibodies.
Panels (B1–4) show sortilin and Aβ labeling with parallel intensity among plaques in the ML. Panels (C1–4) show an overall colocalization of sortilin with Aβ in the
plaques, while the fluorescent intensity is not parallel at local areas between the two markers (merged color appears more greenish, reddish or neutrally yellow).
Panels (D1–4) show sortilin labeling coexisting but not colocalizing with dystrophic neurites (DNs) with distinct synaptophysin (SYN) immunoreactivity at the same
plaques. Panels (E1–4) show extracellular sortilin labeling coexisting with DNs with weak phosphorylated-Tau (p-Tau) reactivity. Panels (F1–4) show sortilin plaques
surrounded by hypertrophic astrocytes with bright GFAP immunofluorescence. Panels (G1–4) display colocalization of extracellular sortilin and ApoE labeling at
plaques. Scale = 100 µm in (A) applying to all image panels.
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used, with densitometric data obtained from the same gyral
region.
Compared to control, sections preheated at 65◦C for 1 h
and 3 h had more intense Aβ immunolabeling, especially along
the pia, over layer I, in the WM and at individual sites of
cerebral vasculature (i.e., cerebral amyloid angiopathy, CAA;
Figures 7A–C). The mean density of Aβ labeling measured over
layers I–VI increased to 433.4 ± 134.3% and 470.9 ± 146.2% in
the sections preheated for 1 h and 3 h, respectively, relative to
control (100± 37.3%), exhibiting an overall difference among the
three groups (P = 0.0003, KWI = 16.1), with significant difference
between the control and both preheated groups, but not between
the groups heated for 1 h and 3 h, by post hoc test (Figure 7D).
On the contrary, section preheating did not alter the pattern and
intensity of sortilin labeling (Figures 7E–H).
Section pretreatment with formic acid for 1 h and 3 h also
greatly enhanced Aβ labeling relative to untreated controls,
with the effect readily maximized by 1 h treatment therefore
presented below. Quantitatively, the mean density of Aβ labeling
in formic treated sections increased significantly (P < 0.0005,
paired t-test), to over 4-fold (433.4 ± 134.3%) relative to
untreated sections (100 ± 32.2%; Figures 7I,J,M). Again, formic
acid treatment did not affect the distribution or intensity of
sortilin labeling (Figures 7K–M). Pretreatment of sections with
guanidine HCl for either 1 h or 3 h (not shown) appeared to
enhance Aβ labeling slightly (however, not reached significance),
relative to untreated control (Figures 7N,O,R). The distribution
or the overall amount of sortilin labeling was not different
between the treated and untreated sections (Figures 7P–R).
Sortilin Fragments were Elevated in AD
Relative to Control Human Cortical Lysates
Western blot was used to explore the putative sortilin products
found deposited at neuritic plaques, with an attempt to identify
potential dependent effect of the presence of amyloid pathology
as well as brain aging. Thus, temporal neocortical samples
(n = 9/group, from the frozen hemisphere) were obtained from
the cases in which the fixed contralateral hemispheres were
pathological examined (see Supplementary Table S1). Cortical
lysates were immunoblotted with the two sortilin antibodies, and
antibodies to APP, BACE1 and p-Tau (as pathological controls).
The rabbit sortilin antibody blotted the principal band migrated
at ∼100 kDa, which appeared thicker in the lysates from the
AD and Aged relative to Mid-age groups. Another prominent
band blotted by this antibody migrated at ∼15 kDa, which was
present in lysates from the AD and Age groups, denser in the
former, while it was absent or minimal in the lysates from
Mid-age subjects (Figure 8A). The medians of normalized (to
β-actin signal) densities of the 100 kDa band were significantly
different in the AD (mean ± SD = 209.6 ± 9.4%, same format
below), Aged (192.2 ± 29.3%) and Mid-age (147.2 ± 38.8%)
groups (P = 0.0220, Kruskal-Wallis statistic index, i.e., KWI,
7.6), with Dunn’s Multiple Comparison Test reported a statistical
difference between the AD and Mid-age groups (Figure 8E1).
The median densities of the 15 kDa product were different in
the three groups (P < 0.0001, KWI = 21.3), with post hoc test
indicating a significant increase in the AD (190.2 ± 34.7%)
relative to Aged (44.9± 27.1%) and Mid-age (6.8± 7.7%) groups
(Figure 8E2). A light ∼40 kDa band was also visualized by
the rabbit antibody in some AD and Aged cases, but not in
the Mid-age group (Figure 8A) (not quantified as it was not
consistently present). Different from the rabbit antibody, the goat
sortilin antibody only blotted the ∼100 kDa band (Figure 8B,
quantitative data not shown), which showed a parallel trend in
density between the cases as that blotted by the rabbit antibody.
Immunoblotted p-Tau products occurred in large amounts in
the lysates from the AD cases, appearing as a smear of bands
≤70 kDa (Figure 8C). The median density of the p-Tau products
was increased in the AD group (1455.1 ± 745.0%) relative to
Aged group (109.4 ± 205.5%) and Mid-age group (2.5 ± 3.8%)
(P < 0.0001, KWI = 20.2) (Figure 8E3). The bands of full-length
APP protein (∼100 kDa) blotted with the 6E10 antibody
appeared to be denser among the AD cases (Figure 7E), with an
overall difference of its levels between AD (183.9± 13.2%), Aged
(151.6± 27.4%) and Mid-age (88.1± 43.9%) groups (P = 0.0003,
KWI = 16.0), elevated in the AD relative to the Mid-age groups
by post hoc test (Figure 8E4). The amount of BACE1 protein
(∼70 kDa) appeared to be increased among the AD cases relative
the other two groups (Figure 8D), with densitometry indicating
an overall difference (P = 0.0003, KWI = 16.0) between the
AD (138.7 ± 15.1%), and Aged (118.2 ± 22.1%) and Mid-age
(105.9 ± 16.2%) groups, and significant difference between the
AD and Mid-age groups by post hoc test (Figure 8E5). Amounts
of β-actin (used as a total protein loading control) and β-tubulin
(used as a neuronal protein control) appeared to be comparable
between the samples (Figure 8D).
DISCUSSION
Full-Length Sortilin Is Enriched in the
Somatodendritic Compartment of Cerebral
Neurons
Sortilin is a type I transmembrane protein consisted of 831 a.a.
residues in Homo sapiens, with a long extracellular N-terminal
sequence (755 a.a. in length), a single-pass transmembrane
domain (a.a. 756–779) and a short intracellular C-terminal tail
(a.a. 780–831) (Westergaard et al., 2004; Hermey, 2009). First
cloned from human brain (Petersen et al., 1997), sortilin is
also called as neurotensin receptor-3 for an initially identified
role in neurotensin signaling (Mazella et al., 1998; Sarret et al.,
2003). Follow-up cell biology studies indicate that it plays a
general role in sorting/trafficking of membrane proteins between
intracellular organelles (Strong et al., 2012; Mortensen et al.,
2014; Kjolby et al., 2015). Sortilin is also known as an ApoE
receptor, and may play a key role in lipoprotein metabolism and
involve in some cardiovascular and metabolic disorders (Carlo,
2013; Coutinho et al., 2013; Kjolby et al., 2015). In the nervous
system, sortilin is shown to regulate the signaling of nerve growth
factors and progranulin, which may relate to disease mechanisms
underlying some neurological and mental disorders (Nykjaer
et al., 2004; Chen et al., 2005; Hu et al., 2010; Yang et al., 2011,
2013).
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FIGURE 7 | Comparative characterization of the effect of antigen retrieval pretreatments on sortilin and Aβ labeling using neocortical sections from cases with severe
cerebral amyloid pathology. Adjacent sections of the precentral and postcentral gyri from four cases are first subjected to an antigen retrieval condition, with the
treated and untreated sections subsequently processed together for immunohistochemistry. Optic densities measured from the same gyrus are normalized to the
mean calculated based on the densities obtained from the untreated sections, and plotted in reference to individual sections (totally eight sections). Aβ
immunoreactivity in sections preheated at 65◦C for 1 h and 3 h is increased in overall intensity, and specifically in layer I, WM and vascular sites (i.e., cerebral amyloid
angiopathy, CAA), relative to untreated (room temperature) control, significantly between the treated and untreated groups but not between the 1 h and 3 h groups
by Kruskal-Wallis analysis with post hoc test (A–D). On the contrary, sortilin immunoreactivity is not altered in the preheated relative to untreated sections (E–H).
Formic acid (100%) treatment for 1 h also greatly enhances Aβ labeling, but has little effect on sortilin labeling (I–M) (paired t-test). Guanidine Hydrochloride (HCl;
5 M) pretreatment for 1 h slightly increases Aβ labeling not reached significance (paired t-test), and it has no effect on sortilin labeling related to untreated control
(N–R). Cortical layers are marked in the image panels. ∗p < 0.05. Scale bar = 100 µm in (A) applying to all image panels.
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In this study, we have characterized the normal expression
pattern of sortilin in adult human cerebrum with two antibodies
targeting separately to the extracellular and intracellular
domains. The specificity of the antibodies has been vigorously
checked with three approaches, i.e., gene knock-out system,
immunogenic peptide absorption and primary antibody
omission. Since both antibodies essentially only label the
∼100 kDa band in immunoblot of adult/normal rodent and
human brain lysates, the immunolabeling seen microscopically
would reflect the expression of full-length sortilin in vivo. Based
on morphological characteristics, cortical and hippocampal
principal neurons express high levels of the full-length
protein, particularly in the somatodendritic compartment.
The labeled granular elements seen in the somata and dendrites
would represent intracellular organelles wherein protein
sorting/trafficking takes place (Petersen et al., 1997; Nielsen
et al., 2001; Gelling et al., 2012).
Often it is difficult with immunolabeling to determine
whether a protein is localized to synaptic structures under the
light microscope, especially in human brain samples obtained
with postmortem delay. The finding of sortilin immunolabeling
to the TE of hilar mossy cells and CA3 pyramidal neurons in
normal human brain is remarkable. The visualization of this
complex dendritic spine formation by both the extracellular
and intracellular domain antibodies strongly suggests that the
full-length sortilin protein is actually enriched at postsynaptic
sites. Therefore, sortilin could play a physiological role in
sorting/recycling of postsynaptic proteins, which could be
important for synapse function and plasticity.
Sortilin Fragments Are a Prominent
Constituent of Senile Plaques in Human
Cerebrum
Recent studies have explored sortilin in relevance to AD and
age-related dementia at genomic, protein and cell biology levels.
So far, no data have shown that sortilin gene mutation or
polymorphic variation increases the risk of developing AD
(Zeng et al., 2013). Notably, a late study reports that the SNP
rs17646665 located in a non-coding region of SORT1 gens is
associated with a reduced risk for AD (Andersson et al., 2016).
Three studies (to the best of our knowledge) have analyzed the
100 kDa sortilin protein in postmortem human brains, with
its levels found either preserved in AD patients and subjects
with mild cognitive impairment relative to people with normal
cognition at death (Mufson et al., 2010), or elevated among AD
relative to control elderly (Finan et al., 2011; Saadipour et al.,
2013). Cell biology and proteomics studies suggest a regulatory
interplay between sortilin and the amyloidogenic proteins. Thus,
sortilin can mediate APP and BACE1 trafficking (Finan et al.,
2011; Saadipour et al., 2013; Yang et al., 2013), while BACE1 and
γ-secretase may catalyze sortilin proteolysis (Nyborg et al., 2006;
Hemming et al., 2009).
In the present study, we show that a sortilin C-terminal
antibody visualizes extracellularly deposited products in the
human brains with cerebral amyloid pathology. The smallest
amount of microscopically detectable deposits appears fibrillary,
present in the neuropil covering areas about the sizes
of neuronal nuclei and somata. The deposits appear to
accumulate locally to form mini-plaques, dense-packing and
ring-like mature-looking plaques. Neither the isolated deposits
nor plaques occur preferentially surrounding the neuronal
somata. Also, the deposits are not detectable inside neuronal
somata and large dendrites. Quantitative analyses based on
fractional areal measurement of individual plaques or collective
densitometry of labeled profiles indicate a correlation between
sortilin and Aβ deposition in the human cerebrum in a
brain region/lamina- and case-dependent manner. Double
immunofluorescent characterizations with a panel of markers
co-existing at neuritic plaques, i.e., SYN, p-Tau, GFAP and ApoE
(Kida et al., 1995; Zhang et al., 2009; Cai et al., 2010, 2012; Sadleir
et al., 2016), show a colocalization of sortilin deposits in this type
of amyloid plaques.
As elaborated in the ‘‘Introduction’’ Section, senile or neuritic
plaques are historically referred to the silver stained lesions
consisted of DNs and amorphous material, i.e., the amyloid
product recognized later. In Aβ antibody stain, compact plaques
in primitive, dense-packing or cored forms appear to closely
represent neuritic plaques (while the so-called ‘‘burn-out’’
plaques may lack or contain only a small amount of DNs;
Delaère et al., 1991). Aβ antibodies also label diffuse plaques as
well as vascular and meningeal amyloidosis that often co-exist
with compact plaques in the brain. Antigen retrieval methods,
especially formic acid treatment, are routinely applied to Aβ
immunohistochemistry. Diffuse plaques can show fairly dense
labeling and mix with compact plaques in the same microscopic
field. Thus, microscopic differentiation between the two types
may not be always conclusive. In fact, inter-laboratory and inter-
experimental inconsistency exists in the assessment of plaque
lesions (Alafuzoff et al., 2008). Our comparative analyses on the
effect of antigen retrieval indicate that section pretreatment with
formic acid or heating essentially does not alter the amount and
pattern of sortilin deposition, although dramatically enhances Aβ
labeling and affects plaque appearance. Thus, the extracellular
sortilin immunolabeling appears to be highly reproducible when
used to visualize neuritic-like plaques in postmortem human
brain.
Collectively, the data obtained from the human brains
through comparative immunohistochemical and immunoblot
assessments with the extracellular and intracellular domain
antibodies allow us to conclude that the extracellularly deposited
sortilin products must be the fragments rather than the parent
protein. Specifically, the 15 kDa fragments detected only by
the C-terminal antibody appear to be the major culprit behind
the extracellular lesions. The levels of these fragments are
dramatically elevated in the cortical lysates from AD human
brains with amyloid pathology relative to aged/mid-age controls
without microscopically overt amyloidosis.
Sortilin Neuropathology Might Relate to
Synaptic Degeneration
As an initially observed human pathology, many mechanistic
questions await to address, such as how and why sortilin
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FIGURE 8 | Western blot characterization of sortilin products in AD relative to aged and mid-age human temporal neocortical lysates. Samples in the AD group are
from cases (n = 9) with pathologically confirmed amyloid deposition in the contralateral hemisphere, scored ≥ B. Samples in the Aged and Mid-age groups are from
cases without microscopically evident amyloidosis. Panels (A–D) illustrate a set of representative images (three cases per group) of immunoblots assayed with sortilin
and AD related markers, as indicated. Panels (E1–5) show the quantification and statistical result (Kruskal-Wallis non-parametric test with post hoc test, same for
below) for each marker based on data from nine cases of each group. The rabbit and goat antibodies detect the same ∼100 kDa band representing the full-length
sortilin protein, with its median density elevated in the AD relative to Mid-age groups (A,B,E1). The rabbit antibody additionally detects a major fragment at ∼15 kDa,
with its levels elevated in the AD group relative to Aged and Mid-age groups (A,E2). Immunoblotted phosphorylated tau (p-Tau) products appear as a smear of
bands less than 70 kDa, with the levels measured for 20–70 kDa bands dramatically elevated in the AD relative to Aged and Mid-age groups (C,E3). Levels of
amyloid precursor protein (APP) and β-secretase-1 (BACE1) are also elevated in the AD as compared to the Mid-age group (D,E4,5). Western blot application: 15%
SDS-PAGE gel and 35 µg equal protein loading for sortilin and p-Tau antibodies; 10% SDS-PAGE gel and 35 µg equal protein loading for other antibodies. P value
for the overall difference between groups is indicated for each marker, with statistically significant inter-group difference (∗P < 0.05) by post hoc also marked in the
graph.
deposition occurs. Our current data allow some preliminary
interrogation on a few issues, in reference to existing literature.
The first one involves whether sortilin deposition occurs as a
direct consequence of amyloidogenesis. While sortilin deposits
coexist with Aβ at neuritic-like plaques in the gray matter,
they are not evidently present along with meningeal and
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vascular β-amyloidosis or in areas with typical diffuse Aβ
deposition in the gray and WMs. Accordingly, sortilin deposition
could not be coherently explained as a passive event resulted
from absorptive binding by Aβ. Neither sortilin full-length
nor deposited products are labeled in the DNs. Therefore, it
appears unlikely that the sortilin deposits derive from the DNs
via secretase-mediated proteolysis of the parent protein. In
comparison, increased BACE1 labeling can be found in DNs
of neuritic plaques, swollen axons in the WM as well as in
vascular and meningeal cells, implicating a potential role of Aβ
overproduction by local cellular profiles for site-specific cerebral
β-amyloidosis (Cheng et al., 2014; Deng et al., 2014; Yan et al.,
2014; Xue et al., 2015; Devraj et al., 2016).
The second issue is about the anatomic origin of the
sortilin deposits. Labeling of the full-length protein is localized
primarily to neuronal profiles, enriched in the somatodendritic
rather than axonal profiles (as discussed in the first part of
‘‘Discussion’’ Section). The giant spine formations, TE, are
distinctly labeled. The labeling is also intense in the ML of the DG
and the stratum radiatum of Ammon’s horn/subiculum likely in
dendritic elements. Thus, dendritic branches and spines could
be a major origin of the sortilin deposits. Such a notion fits well
with the overall region-specific distribution of sortilin plaques in
the neuropil of the gray matter, including the ML and stratum
radiatum wherein neuronal somata are rare but plaques are
distinct. Synaptic degeneration is considered the most important
anatomical basis underlying cognitive decline in AD. Plaque
formation appears to be a continuing process tightly associated
with synaptic degeneration, with dendritic spine loss and axonal
terminal degeneration/dystrophy at the lesion sites (Gonatas
et al., 1967; Masliah et al., 1991; Ferrer et al., 1998; Adalbert and
Coleman, 2013; Yan et al., 2014; Herms and Dorostkar, 2016;
Sadleir et al., 2016). Sortilin fragments might derive largely from
degenerating dendritic spines and branches therefore accumulate
preferentially at neuritic-like plaques.
The third issue relates to the biochemical process that might
underlie the formation of sortilin fragments. Some in vitro and
in vivo data suggest that the extracellular domain of sortilin can
shed off as soluble products (Navarro et al., 2002; Molgaard et al.,
2016; Ogawa et al., 2016). The ∼15 kDa products are exclusively
immunoblotted by the C-terminal antibody, with the plaque
labeling completely diminished by the corresponding blocking
immunogenic peptide. With this information and in reference to
the molecular weight (∼15 kDa), the deposited sortilin products
could be predicted to contain the C-terminal tail, transmembrane
domain and a short part of the extracellular sequence (roughly
a.a. 670–831 according to online protein analysis tools), without
considering the situation of protein modification (the C-terminal
region contains two putative phosphorylation sites). The sortilin
fragments might be formed after the extracellular domain is
cleaved off, and aberrantly accumulate site-specifically along
with dendritic/spine degeneration of local neurons during plaque
pathogenesis.
In summary, we have identified sortilin fragments as a new
component of the abnormally deposited protein products in
senile plaques in the human cerebrum. This sortilin extracellular
pathology is fairly preferentially associated with neuritic-like
amyloid plaques, but rarely occurs around the pia, at vascular
wall and in regions with typical diffuse Aβ deposition. The
plaque-like sortilin labeling is not affected by antigen retrieval
methods that enhance Aβ immunoreactivity. The ∼15 kDa
fragments appear to be a major form of the deposited
components, which is predicted to derive largely from the
C-terminal region likely including the transmembrane part of
the parent protein. Mechanistically, we speculate that these
fragments are formed along with the degeneration of largely the
dendritic spines and fine branches.
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